---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026402"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:25:58.851892+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports Q4 net income $4.5M vs loss; ARCALYST revenue $122.5M in FY2022

## Summary
- ARCALYST net product revenue $39.9M in Q4, $122.5M full-year 2022; FY2023 guidance $190-205M.
- Total revenue $61.9M Q4, $220.2M full-year; license revenue from Roche/Genentech and Huadong.
- Net income $4.5M Q4 vs loss $36.3M; full-year net income $183.4M includes $172.3M tax benefit.
- Cash $190.6M, no debt; expects cash to fund operations into at least 2025.
- KPL-404 Phase 2 RA trial advancing; efficacy data expected first half 2024.

## SEC filing metadata
- accession: 0001104659-23-026402
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/0001104659-23-026402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/tm237813d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026402
- JSON: https://secwatch.observer/filing/0001104659-23-026402.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026402.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported the fiscal year ended December 31, 2022 results: revenue Total revenue for the full-year 2022 was $220.2 million, net income Net income for the full-year 2022 was $183.4 million. Guidance reaffirmed.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: Total revenue for the full-year 2022 was $220.2 million
  - Net income: Net income for the full-year 2022 was $183.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 28, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/0001104659-23-026402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.